Ariane Tom, Phd

Ariane Tom, Phd Email and Phone Number

Pioneering Neurotech Investments 🧠🦾🤖 Kaleida Capital | Stanford University @ Kaleida Capital
Ariane Tom, Phd's Location
San Diego, California, United States, United States
Ariane Tom, Phd's Contact Details

Ariane Tom, Phd personal email

Ariane Tom, Phd phone numbers

About Ariane Tom, Phd

Dr. Ariane Tom is Founder & Managing Director of Kaleida Capital, investing in neurotech & the future of computation. Throughout her academic career at Stanford, Ariane spearheaded research programs in neural interfaces with applications in brain-mapping, prosthetics, drug delivery, and neuromodulation. She is a published co-author in top-tier research journals Science Magazine and Nature Portfolio, collaborating across disciplines with luminaries Karl Deisseroth (optogenetics & CLARITY), Zhenan Bao (electronic skin), and Sergiu Pasca (organoids). Beyond the bench, she has applied over a decade of research insight to venture capital, patent law, and public policy, cultivating a top-performing investment track record by identifying and backing technologies of multiple Nobel Laureates. She has served the Boards of several companies spanning neuroimaging, cancer diagnostics, drug discovery, and immunotherapy. Today, Ariane is a prominent voice for neurotechnology innovation and is a frequent speaker at events where she discusses neurotechnology development and investment landscape. Ariane holds a B.S. in Materials Science & Engineering, an M.S. in Bioengineering, and a Ph.D. in Bioengineering, all from Stanford University.

Ariane Tom, Phd's Current Company Details
Kaleida Capital

Kaleida Capital

View
Pioneering Neurotech Investments 🧠🦾🤖 Kaleida Capital | Stanford University
Ariane Tom, Phd Work Experience Details
  • Kaleida Capital
    Founder & Managing Director
    Kaleida Capital May 2022 - Present
    San Diego , Ca, Us
    Kaleida Capital is an early stage venture fund investing in neurotech & the future of computation.Speaking Engagements: “AI in Healthcare”- WIB at BIO International Convention 2024"Bioconvergence - Opportunity at the Intersection". LSI Emerging Medtech Summit, USA 2024."Early-Stage Neurotech Investment". North American Neuromodulation Society Annual Meeting 2024“The Frontiers of DeepTech”. RAISE Emerging Manager Global Summit 2023.“Investing in Brain Health Technology Innovation”. Brain Capital Innovation Summit 2023.“Leading Investments in Longevity”. Milken Global Conference 2023.“Neurotech Investment Outlook” Neurotech Leaders Forum 2022.“Neurotechnology Development and Commercialization” IEEE Brain Discovery Workshop 2022.Accolades: *1 of 36 firms selected for Recast Capital Accelerate Program (Cohort 1, 2023)*1 of 12 firms selected for Recast Capital Enablement Program (Cohort 6, 2023) *1 of 20 firms selected for Bridge Funding Global (2023) by LP committee including senior leadership of Sapphire Ventures, Pivotal Ventures, Cendana Capital*1 of 50 firms graduating from Founder’s Institute VC Lab Accelerator (Cohort 8, 2022)
    View
  • Anthropic
    Investor
    Anthropic Jun 2024 - Present
    Making AI systems you can rely on - Anthropic (developer of Claude) is a Public Benefit Corporation, whose purpose is the responsible development and maintenance of advanced AI for the long-term benefit of humanity.
    View
  • Manifest Technologies
    Lead Investor & Board Observer
    Manifest Technologies Aug 2023 - Present
    Manifest Technologies is revolutionizing psychiatric drug development through its AI-powered precision neuroscience and computational neuroimaging platform.
  • Milken Institute
    Member | Milken Institute Young Leaders Circle
    Milken Institute Feb 2024 - Present
    Santa Monica, California, Us
    The YLC is a group of 300 intellectually curious, motivated and philanthropic young professionals from a range of industries around the world who support the Milken Institute and its mission.
    View
  • One Mind
    Advisor | Mental Health Startup Accelerator
    One Mind Jan 2023 - Present
    Napa, California, Us
    The One Mind Accelerator backs visionary founders of early-stage startups with a $100,000 investment and 10 weeks of intensive programming to build category-defining companies that improve the lives of people living with mental illness.For 2023 cohort, referred 3 of 11 participating companies from Kaleida pipeline: *Cereteype Neuromedicine: advanced neuro-image acquisition and analytics that de-risk and accelerate development of psychiatric and neurological therapies.*Motif Neurotech: minimally invasive bioelectronic implants that monitor and treat severe mental health conditions.*Tetricus Labs: leveraging AI computational neuroscience to deliver the right diagnosis and treatment recommendation for every patient.
    View
  • Nucleate
    Industry Advisor | Venture Capital
    Nucleate Nov 2021 - Present
    Boston, Us
    Keynote Speaker: “Navigating Mentorship as a Biotech Entrepreneur”. Nucleate San Diego -Activator Program Kickoff Event, 2023.
    View
  • Biocom California
    Committee Member | Capital Development & Partnering
    Biocom California Jul 2022 - Present
    San Diego, Ca, Us
    A group of board-level directors, investors, and industry leaders implementing financial capital development activities to accelerate the growth of the life science industry in California. *Nominee for Biocom Catalyst Award 2022
    View
  • Anzu Partners
    Investor | Venture Capital
    Anzu Partners Nov 2019 - Mar 2022
    Washington, District Of Columbia, Us
    Early backer of 2 Nobel Prize -winning technologies and Board Observer at 3 portfolio companies, resulting in improved fund performance at a deep-tech fund w/ ~$1B AUM.*Carolyn Bertozzi, InterVenn Biosciences, Nobel Prize in Chemistry 2022*Jennifer Doudna, Excision Biotherapeutics, Nobel Prize in Chemistry 2020
    View
  • Excision Biotherapeutics
    Investor
    Excision Biotherapeutics Feb 2021 - Feb 2022
    San Francisco , Ca, Us
    *Sourced and led diligence for $60M Series A financing, Feb 2021.Excision develops CRISPR-based therapies to cure viral infectious diseases. Pre-clinical in vivo studies for EBT-101 were the first to demonstrate removal of SIV proviral DNA in non-human primates, indicating potential for the development of a functional cure for HIV in human patients.
    View
  • Intervenn Biosciences
    Investor & Board Observer
    Intervenn Biosciences Jul 2020 - Feb 2022
    South San Francisco, California, Us
    *Sourced and led diligence for $34M Series B financing, July 2020*Syndicate member in $201M Series C round led by SoftBank, July 2021InterVenn's AI-enabled mass spectrometry platform unlocks scalable analysis of glycosylated elements from patient blood samples, permitting a new category of disease biomarkers for improved cancer diagnostics and therapeutic development.
    View
  • Immunoscape
    Board Observer
    Immunoscape Dec 2019 - Feb 2022
    Singapore, Sg
    ImmunoScape's platform combines mass cytometry, single cell sequencing, and bioinformatics to perform high-dimensional profiling of T-cell populations for development of immunotherapies and therapeutic vaccines.
    View
  • Bioskryb Genomics
    Board Observer
    Bioskryb Genomics Dec 2019 - Feb 2022
    Durham, North Carolina, Us
    BioSkryb is commercializing a new method for whole genome amplification, PTA, which accurately recovers more than 95% of the genomes of single cells and greatly improves the ability to detect rare mutations.
    View
  • Schox Patent Group
    Associate | Patent Prosecution & Strategy For Startups
    Schox Patent Group Jan 2018 - Sep 2018
    San Francisco, California, Us
    Directed interactions with executive and engineering leads of venture-backed technology startups to build valuable patent portfolios and develop IP strategy; Identified key features of inventions to craft comprehensive and high-quality patent applications in U.S. and foreign jurisdictions; Motivated and fostered new client relationships sourced from broad academic networks at Stanford, UCSF, and UC Berkeley.
    View
  • Stanford University
    Doctoral Research Fellow | Next-Generation Neural Interfaces
    Stanford University Jun 2012 - Dec 2017
    Stanford, Ca, Us
    Spearheaded an interdisciplinary research program focusing on flexible bioelectronic neural interfaces with applications in brain-mapping, prosthetics, and neuromodulation. Projects included: brain-polymer hybrids (CLARITY), electronic skin, and genetically-targeted polymer synthesis in active mammalian neurons. Co-author of two publications in Science Magazine (see below links).Patent: "Genetically-Targeted Chemical Assembly: Building Functional Structures and Materials in Living Cells, Tissues, and Animals" (PCT Application Serial No. US2020/063403)
    View
  • University Of California, Berkeley
    Research Scientist | Physical Principles Governing Neural Stimulation And Drug Delivery
    University Of California, Berkeley Aug 2011 - May 2012
    Berkeley, Ca, Us
    Engaged in several collaborative research efforts between UC Berkeley Engineering and UCSF Neurosurgery. Projects include: uEcoG arrays in rodents and cyborg beetles; Peptide-polymer conjugate micelles for delivery of doxorubicin to brain tumors; Thin films for delivery of XAV939 to optic nerve
    View
  • Stanford University
    Research Scientist | Prosthetic Cornea
    Stanford University Jan 2009 - Jun 2011
    Stanford, Ca, Us
    Devised a photolithographic method to precisely tune the curvature of interpenetrating hydrogel networks for a prosthetic cornea. Synthesis and characterization of 3D PEG/PAA hydrogel networks under various photolithographic patterning conditions significantly decrease manufacturing costs of curved polymeric lenses.Co-Inventor, patent application: "Three-Dimensionally Shaped Interpenetrating Network Hydrogels" U.S. Publication No. US20100174021A1. 2010.
    View
  • Stanford University
    Research Scientist | High-Throughput Gene Sequencing Of Individual Organism'S Immune Repertoire
    Stanford University May 2008 - Sep 2008
    Stanford, Ca, Us
    In college, worked with Dr. Stephen Quake on one of the first demonstrations of high-throughput sequencing to determine the complete diversity of of an individual organism's antibody repertoire. We discovered that the abundance distributions of both the VDJ repertoire and antibody heavy-chain diversity were similar between individuals, that VDJ usage is not uniform, that individuals can have highly correlated VDJ repertoires, and that convergent evolution of identical heavy-chain sequences is unexpectedly common. This work will preface current-day immuno-genomics/immunotherapy (therapeutics for cancer that influence immune response). Weinstein JA, Jiang N, White RA 3rd, Fisher DS, Quake SR. High-throughput sequencing of the zebrafish antibody repertoire. Science. 2009;324(5928):807–810. doi:10.1126/science.1170020
    View
  • University Of California, Riverside
    Research Assistant | Foundations Of Applied Gene Editing & Characterization
    University Of California, Riverside 2005 - 2006
    Riverside, Ca, Us
    In high school, developed lines of genetically-modified insects using early 2000s gene editing techniques to engineer mosquitos from carrying transmissible disease (e.g., malaria, yellow fever). This work led to my first publication. Arensburger P, Hice RH, Zhou L, Smith RC, Tom AC, Wright JA, Knapp J, O'Brochta DA, Craig NL, Atkinson PW. Phylogenetic and functional characterization of the hAT transposon superfamily. Genetics. 2011 May;188(1):45-57. doi: 10.1534/genetics.111.126813.
    View

Ariane Tom, Phd Skills

Biotechnology Nanomaterials Chemical Engineering Bioelectronics Organic Semiconductors Characterization Materials Characterization Life Sciences Design Of Experiments Polymer Science And Engineering Nanobiotechnology Biomaterials Soft Materials Synthesis Chemical Spectroscopy Microfabrication Mems Clarity Tissue Clearing Tissue Engineering Drug Delivery Neural Interfaces Neural Networks Biosensors Patent Prosecution

Ariane Tom, Phd Education Details

  • Stanford University
    Stanford University
    Bioengineering
  • Stanford University
    Stanford University
    Bioengineering
  • Stanford University
    Stanford University
    Materials Science & Engineering
  • Stanford University
    Stanford University
    Strategic Analyst At Doe Office Of Energy Efficiency And Renewable Energy (Eere)
  • Harvard Business School Online
    Harvard Business School Online
    Finance And Financial Management Services

Frequently Asked Questions about Ariane Tom, Phd

What company does Ariane Tom, Phd work for?

Ariane Tom, Phd works for Kaleida Capital

What is Ariane Tom, Phd's role at the current company?

Ariane Tom, Phd's current role is Pioneering Neurotech Investments 🧠🦾🤖 Kaleida Capital | Stanford University.

What is Ariane Tom, Phd's email address?

Ariane Tom, Phd's email address is ar****@****ers.com

What is Ariane Tom, Phd's direct phone number?

Ariane Tom, Phd's direct phone number is (888) 775*****

What schools did Ariane Tom, Phd attend?

Ariane Tom, Phd attended Stanford University, Stanford University, Stanford University, Stanford University, Harvard Business School Online.

What skills is Ariane Tom, Phd known for?

Ariane Tom, Phd has skills like Biotechnology, Nanomaterials, Chemical Engineering, Bioelectronics, Organic Semiconductors, Characterization, Materials Characterization, Life Sciences, Design Of Experiments, Polymer Science And Engineering, Nanobiotechnology, Biomaterials.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.